Genentech Reports P-III (BALATON) and (COMINO) Study Results of Vabysmo (faricimab-svoa) for Retinal Vein Occlusion
Shots:
- The P-III (BALATON) study in 553 patients with branch retinal vein occlusion & (COMINO) study in 730 patients with central retinal or hemiretinal vein occlusion evaluating Vabysmo vs aflibercept in a ratio (1:1) for 24wks.
- The trial met their 1EPs & showed non-inferior visual acuity gains over aflibercept, avg. vision gains from baseline were comparable b/w 2 treatment groups. The 2EPs showed rapid and robust drying of retinal fluid from baseline as measured by reduction in CST, reductions in CST were comparable across treatment arms in both studies
- In pre-specified exploratory EPs in both studies, patients showed an absence of leakage in the retina (34% vs 21% & 44% vs 30%). The safety profile was consistent with prior trials
Ref: Businesswire | Image: Genentech
Related News:- Genentech Reports P-III (BALATON) and (COMINO) Studies Results of Vabysmo (faricimab-svoa) for the Treatment of Retinal Vein Occlusion
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
